Ailte I, Chauhan SK, Prasmickaite L, Bassarova AV, Poissonnier A, Feenstra M, Nyakas M, Johannessen B, Ryder T, Hermann R, Frich L, Holth A, Inderberg EM, Jespersen H, Flørenes VA, Kyte JA, Mælandsmo GM, Egeland EV(2026) CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade Front Oncol, 16, 1815008 DOI 10.3389/fonc.2026.1815008, PubMed 42158424
Eide HA, Grut H, Jebsen P, Kyte JA, Bratland Å(2026) Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial Radiother Oncol, 219, 111514 DOI 10.1016/j.radonc.2026.111514, PubMed 41916446
Svalheim KG, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, Kyte JA(2026) Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer Breast, 86, 104704 DOI 10.1016/j.breast.2026.104704, PubMed 41581361
